Start Date
March 9, 2018
Primary Completion Date
September 29, 2019
Study Completion Date
September 29, 2019
Nivolumab
Specified dose on specified days
Ipilimumab
Specified dose on specified days
Local Institution, Lima
Local Institution, Viedma
Local Institution, Lancaster
Local Institution, Sayre
Local Institution, Langhorne
Local Institution, Großhansdorf
Local Institution, Charleston
Local Institution, Columbus
Local Institution, Lincoln
Local Institution, Gerlingen
Local Institution, Gauting
Local Institution, St. George
Local Institution, San Francisco
Local Institution, Hackensack
Local Institution, Montreal
Local Institution, Dresden
Local Institution, Lima
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY